Skip to main page content
U.S. flag
See More

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015:66:455-70.
doi: 10.1146/annurev-med-050913-022545. Epub 2014 Oct 17.

Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors

Christopher J Lord  1 , Andrew N J Tutt, Alan Ashworth
Affiliations
Review

Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors

Christopher J Lord et al. Annu Rev Med. 2015.

Abstract

The genetic concept of synthetic lethality, in which the combination or synthesis of mutations in multiple genes results in cell death, provides a framework to design novel therapeutic approaches to cancer. Already there are promising indications, from clinical trials exploiting this concept by using poly(ADP-ribose) polymerase (PARP) inhibitors in patients with germline BRCA1 or BRCA2 gene mutations, that this approach could be beneficial. We discuss the biological rationale for BRCA-PARP synthetic lethality, how the synthetic lethal approach is being assessed in the clinic, and how mechanisms of resistance are starting to be dissected. Applying the synthetic lethal concept to target non-BRCA-mutant cancers also has clear potential, and we discuss how some of the principles learned in developing PARP inhibitors might also drive the development of additional genetic approaches.

Keywords: BRCA1; BRCA2; breast cancer; drug resistance; ovarian cancer.

PubMed Disclaimer

Publication types

MeSH terms